ABSTRACT
The past decade has witnessed an explosion in studies of biomarkers in psychiatry, paralleling development of high-dimensionality and high-throughput methods for genomic and transcriptomic study. In this section, we selectively review selected efforts to develop psychiatric biomarkers spanning multiple modalities, including genomics, transcriptomics and proteomics and cellular models. We also more briefly address other biomarker strategies drawn from imaging and mobile health, and we consider the emerging role for machine learning and artificial intelligence. In each case, the goal is to understand, broadly speaking, progress toward actionable biomarkers, rather than to catalog every result in what is a rapidly moving field. This section concludes with a discussion of strategies for accelerating biomarker discovery and development for neuropsychiatric diseases.
